Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.44 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | MGAM | O43451 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SI | P14410 | 1/20 | 0.33 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.33 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13871299 | 1.00 | NPSR1 (0.44) | NPSR1GLO1ALOX15ALDH1A1LMNA | |
| SCHEMBL3863889 | 1.00 | NPSR1 (0.44) | NPSR1GLO1ALOX15ALDH1A1LMNA | |
| SCHEMBL29786598 | 0.78 | GLO1 (0.42) | NPSR1GLO1ALOX15ALDH1A1LMNA | |
| SCHEMBL12913210 | 0.77 | GLO1 (0.41) | NPSR1GLO1ALOX15ALDH1A1LMNA | |
| SCHEMBL13871298 | 0.77 | GLO1 (0.41) | NPSR1GLO1ALOX15ALDH1A1LMNA | |
| SCHEMBL948834 | 0.77 | HCAR2 (0.52) | NPSR1GLO1ALOX15ALDH1A1LMNA | |
| SCHEMBL14870465 | 0.74 | HCAR2 (0.45) | NPSR1GLO1ALOX15ALDH1A1LMNA | |
| SCHEMBL4890688 | 0.74 | HCAR2 (0.45) | NPSR1GLO1ALOX15ALDH1A1LMNA | |
| SCHEMBL10463988 | 0.72 | ALOX15 (0.52) | NPSR1GLO1ALOX15ALDH1A1LMNA | |
| SCHEMBL1144348 | 0.72 | ALOX15 (0.52) | NPSR1GLO1ALOX15ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1781673-B1 | SELECTED FUSED HETEROCYCLICS AND USES THEREOF | ASTRAZENECA AB (SE) | 2009-10-21 | — | — | EP | disclosed |
| US-20090099210-A1 | ENANTIOMERS OF SELECTED FUSED HETEROCYCLICS AND USES THEREOF | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | US | disclosed |
| US-7498333-B2 | Enantiomers of selected fused heterocyclics and uses thereof | ASTRAZENECA AB (SE) | 2009-03-03 | — | — | US | disclosed |
| US-20080293744-A1 | Enantiomers of Selected Fused Pyrimidones and Uses in the Treatment and Prevention of Cancer | ASTRAZENECA AB (SE) | 2008-11-27 | — | — | US | disclosed |
| US-20080153854-A1 | NOVEL FUSED HETEROCYCLES AND USES THEREOF | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | US | disclosed |
| US-20070249636-A1 | Selected Fused Heterocyclics and Uses Thereof | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | US | disclosed |
| EP-1781674-A1 | ENANTIOMERS OF SELECTED FUSED PYRIMIDONES AND USES IN THE TREATMENT AND PREVENTION OF CANCER | AstraZeneca AB (SE) | 2007-05-09 | — | — | EP | disclosed |
| EP-1781673-A1 | SELECTED FUSED HETEROCYCLICS AND USES THEREOF | AstraZeneca AB (SE) | 2007-05-09 | — | — | EP | disclosed |
| US-20060063751-A1 | Novel fused heterocycles and uses thereof | ASTRAZENECA AB (SE) | 2006-03-23 | — | — | US | disclosed |
| US-20060041128-A1 | Selected fused heterocyclics and uses thereof | ASTRAZENECA AB (SE) | 2006-02-23 | — | — | US | disclosed |
| WO-2006018627-A1 | SELECTED FUSED HETEROCYCLICS AND USES THEREOF | ASTRAZENECA AB (SE) | 2006-02-23 | — | — | WO | disclosed |
| US-20060041129-A1 | Enantiomers of selected fused heterocyclics and uses thereof | ASTRAZENECA AB (SE) | 2006-02-23 | — | — | US | disclosed |
| WO-2006018628-A1 | ENANTIOMERS OF SELECTED FUSED PYRIMIDONES AND USES IN THE TREATMENT AND PREVENTI ON OF CANCER | ASTRAZENECA AB (SE) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249636-A1 | Selected Fused Heterocyclics and Uses Thereof | SDHA, CYP11B2, NQO1 | NPSR1 2618/4885GLO1 1789/4885ALOX15 943/4885 |
| US-20060063751-A1 | Novel fused heterocycles and uses thereof | RB1, CDK19, PRMT9 | NPSR1 1298/4885GLO1 3033/4885ALOX15 4245/4885 |
| US-20080153854-A1 | NOVEL FUSED HETEROCYCLES AND USES THEREOF | RB1, CDK19, PRMT9 | NPSR1 1298/4885GLO1 3033/4885ALOX15 4245/4885 |
| US-20080293744-A1 | Enantiomers of Selected Fused Pyrimidones and Uses in the Treatment and Prevention of Cancer | DHFR, DPYD, TYMS | NPSR1 2832/4885GLO1 1711/4885ALOX15 1337/4885 |
| US-20060041128-A1 | Selected fused heterocyclics and uses thereof | SDHA, CYP11B2, NQO1 | NPSR1 2618/4885GLO1 1789/4885ALOX15 943/4885 |
| US-20090099210-A1 | ENANTIOMERS OF SELECTED FUSED HETEROCYCLICS AND USES THEREOF | CYP11B2, HCCS, CYP11B1 | NPSR1 1239/4885GLO1 1482/4885ALOX15 1269/4885 |
| US-20060041129-A1 | Enantiomers of selected fused heterocyclics and uses thereof | CYP11B2, HCCS, CYP11B1 | NPSR1 1239/4885GLO1 1482/4885ALOX15 1269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.